Nektar Therapeutics reports Q1 2026 results with non-GAAP EPS -$1.82 (+49% YoY) and revenue $10.9M (+4% YoY), misses EPS but beats revenue estimates
- Q1 2026 net loss totaled $44.9M; quarterly revenue was $10.9M.
- Cash and investments were $731.6M at quarter-end, excluding proceeds from Nektar's April equity offering.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.